How Investors May Respond To PROCEPT BioRobotics (PRCT) Winning Strong EAU Backing For Aquablation

Simply Wall St.03-26 14:06

Earlier in March 2026, PROCEPT BioRobotics highlighted that the European Association of Urology has upgraded Aquablation therapy to a strong recommendation as a surgical option for men with benign ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622388831?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","is_english":true,"pubTime":"2026-03-26 14:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622388831","market":"nz","top_or_hot":-1,"title":"How Investors May Respond To PROCEPT BioRobotics (PRCT) Winning Strong EAU Backing For Aquablation","media":"Simply Wall St.","content":"<div>\n<p>Earlier in March 2026, PROCEPT BioRobotics highlighted that the European Association of Urology has upgraded Aquablation therapy to a strong recommendation as a surgical option for men with benign ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-prct/procept-biorobotics/news/how-investors-may-respond-to-procept-biorobotics-prct-winnin\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Investors May Respond To PROCEPT BioRobotics (PRCT) Winning Strong EAU Backing For Aquablation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Investors May Respond To PROCEPT BioRobotics (PRCT) Winning Strong EAU Backing For Aquablation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-26 14:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-prct/procept-biorobotics/news/how-investors-may-respond-to-procept-biorobotics-prct-winnin><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier in March 2026, PROCEPT BioRobotics highlighted that the European Association of Urology has upgraded Aquablation therapy to a strong recommendation as a surgical option for men with benign ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-prct/procept-biorobotics/news/how-investors-may-respond-to-procept-biorobotics-prct-winnin\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4211","symbol_name":"区域性银行","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-prct/procept-biorobotics/news/how-investors-may-respond-to-procept-biorobotics-prct-winnin","article_id":"2622388831","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-prct/procept-biorobotics/news/how-investors-may-respond-to-procept-biorobotics-prct-winnin","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622388831","pubTimestamp":1774505193,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier in March 2026, PROCEPT BioRobotics highlighted that the European Association of Urology has upgraded Aquablation therapy to a strong recommendation as a surgical option for men with benign prostatic hyperplasia, positioning it as an alternative to transurethral resection of the prostate, especially for those seeking to preserve ejaculatory function.\nThis guideline upgrade, backed by multiple WATER clinical trials and growing international validation including NICE support in the UK,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4211":"区域性银行","ISBC":"投资者银行","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4082":"医疗保健设备","PRCT":"PROCEPT BioRobotics","AIPO":"Defiance AI and Power Infrastructure ETF"},"translate_title":"投资者对PROCEPT BioRobotics(PRCT)为Aquablation赢得EAU的大力支持有何反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIPO":0.61,"PRCT":1.5,"ISBC":1.5},"content_text":"Earlier in March 2026, PROCEPT BioRobotics highlighted that the European Association of Urology has upgraded Aquablation therapy to a strong recommendation as a surgical option for men with benign prostatic hyperplasia, positioning it as an alternative to transurethral resection of the prostate, especially for those seeking to preserve ejaculatory function. This guideline upgrade, backed by multiple WATER clinical trials and growing international validation including NICE support in the UK, underscores how Aquablation and the HYDROS AI-enabled robotic system are increasingly embedded in evidence-based urologic practice. We’ll now explore how Aquablation’s new strong backing in European guidelines could influence PROCEPT BioRobotics’ investment narrative and growth drivers. Find 55 companies with promising cash flow potential yet trading below their fair value.AdvertisementPROCEPT BioRobotics Investment Narrative RecapTo own PROCEPT BioRobotics, you need to believe Aquablation and HYDROS can become a standard surgical option in BPH, driving wider system placement and recurring procedure use despite ongoing losses. The EAU’s strong Aquablation recommendation directly supports the core adoption and utilization catalyst in the near term, but it does not eliminate key risks around reimbursement pressure, competition and the company’s reliance on a single technology platform. The March 12 announcement on HYDROS’ international rollout is especially relevant here, because it links the upgraded European guidelines to a concrete commercialization path for the AI-enabled system in markets like the UK. Together, stronger guideline support and a next generation platform installed across more hospitals could reinforce the existing catalyst of procedure growth, while also amplifying exposure to risks tied to capital budgets and potential shifts of procedures away from hospital settings. However, investors should also be aware that heightened competition and shifting BPH care into outpatient centers could still... Read the full narrative on PROCEPT BioRobotics (it's free!)PROCEPT BioRobotics' narrative projects $563.8 million revenue and $70.4 million earnings by 2028.Uncover how PROCEPT BioRobotics' forecasts yield a $32.50 fair value, a 30% upside to its current price.Exploring Other PerspectivesPRCT 1-Year Stock Price Chart Some of the most optimistic analysts already saw room for revenue to climb toward about US$624.2 million and positive earnings, yet the EAU decision and the risk of BPH procedures moving out of hospitals highlight how differently you could view PROCEPT’s future and why it is worth weighing several viewpoints before deciding what this stock means for your portfolio.Explore 6 other fair value estimates on PROCEPT BioRobotics - why the stock might be worth just $30.44!Decide For YourselfDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your PROCEPT BioRobotics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.Our free PROCEPT BioRobotics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate PROCEPT BioRobotics' overall financial health at a glance.No Opportunity In PROCEPT BioRobotics?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 26 best rare earth metal stocks of the very few that mine this essential strategic resource.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622388831","isCrawlerRequest":true}